NX-1607
- Generic Name
- NX-1607
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Gastric CancerMetastatic Urothelial CarcinomaCervical CancerRichter TransformationOvarian Cancer, EpithelialNon-small Cell Lung Cancer (NSCLC)Microsatellite Stable Colorectal CarcinomaGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMetastatic or Unresectable Melanoma
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT05107674
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath